Researcher.Life Logo

Crohn's and Colitis 360 : Impact Factor & More

eISSN: 2631-827XpISSN: 2631-827X
JournalOpen Access

Key Metrics

CiteScore
1
SNIP
0.35
Recommended pre-submission checks
Powered by Paperpal by Editage

Crohn's and Colitis 360 Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher OXFORD UNIV PRESS
Language English
Frequency Quarterly
Article Processing ChargesUSD 2975
Publication Time12
Editorial Review ProcessDouble anonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorCrohn's and Colitis Foundation
FrequencyQuarterly
Publication Start Year2019
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 12
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble anonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Crohn's and Colitis 360 ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Crohn's and Colitis 360

Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States
  • 8 May 2026
  • 1 Jan 0360
Racial disparities in prevalence, screening, and complications of osteoporosis in patients with inflammatory bowel disease: a retrospective cohort study
  • 26 Apr 2026
  • 1 Jan 0360
Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey
  • 24 Apr 2026
  • 1 Jan 0360
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab
  • 20 Apr 2026
  • 1 Jan 0360
Providing care at a most vulnerable time.
  • 11 Apr 2026
  • 1 Jan 0360
Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
  • 1 Apr 2026
  • 1 Jan 0360
Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States
  • 8 May 2026
  • 1 Jan 0360
Racial disparities in prevalence, screening, and complications of osteoporosis in patients with inflammatory bowel disease: a retrospective cohort study
  • 26 Apr 2026
  • 1 Jan 0360
Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey
  • 24 Apr 2026
  • 1 Jan 0360
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab
  • 20 Apr 2026
  • 1 Jan 0360
Providing care at a most vulnerable time.
  • 11 Apr 2026
  • 1 Jan 0360
Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
  • 1 Apr 2026
  • 1 Jan 0360

FAQs on Crohn's and Colitis 360